Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

36 bytes added, 13:28, 29 September 2018
m
no edit summary
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (C)
|1. [[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Azacitidine_.26_Vorinostat|Azacitidine & Vorinostat]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (C)
|1. [[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Azacitidine_.26_Vorinostat|Azacitidine & Vorinostat]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Azacitidine_.26_Vorinostat|Azacitidine & Vorinostat]]
|style="background-color:#d3d3d3"|Not reported
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Azacitidine_.26_Vorinostat|Azacitidine & Vorinostat]]
|style="background-color:#d3d3d3"|Not reported
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#d3d3d3"|Not reported
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup (E)
|1. [[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|2. [[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#d3d3d3"|Not reported
|-
LookupUsers, editors, emailconfirmed
24,702
edits

Navigation menu